PPR | Jotup

Prairie Provident Reports on AGM Voting Results

Retrieved on:

木曜日, 5月 16, 2024

CALGARY, Alberta, May 15, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces voting results from its annual shareholders' meeting held today.

Key Points:

CALGARY, Alberta, May 15, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces voting results from its annual shareholders' meeting held today.
At the meeting, each of Patrick McDonald, Glenn Hamilton, Dale Miller, Ryan Rawlyk, Matthew Shyba and Kathy Turgeon was elected, by ordinary resolution, as a director of the Company for the ensuing year, to hold office until the close of the next annual meeting of shareholders.
Following are details as to the number of votes cast 'for' the election of each director nominee at the meeting, and the percentage that figure represented of the total shares voted or withheld from voting in respect of that nominee.

Prairie Provident Resources Announces First Quarter 2024 Financial and Operating Results and Michichi Property Update

Retrieved on:

水曜日, 5月 15, 2024

Quartz, Inter Pipeline, Economics, Evi, Conversation, Basal, Bank statement, Sale, MD, PPR, Provost, Princess, TSX, Oil

CALGARY, Alberta, May 15, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its operating and financial results for the first quarter ended March 31, 2024.

Key Points:

CALGARY, Alberta, May 15, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its operating and financial results for the first quarter ended March 31, 2024.
The decrease was a result of lower realized pricing slightly offset by a decrease in royalties and operating costs.
In addition, the decrease was reduced by lower expenses and a gain on property dispositions in the first quarter of 2024.
Prairie Provident has identified more than 40 Basal Quartz potential drilling opportunities targeting light/medium oil on its Michichi lands.

PPR Capital Management Named to Financial Times "The Americas' Fastest-Growing Companies 2024"

Retrieved on:

木曜日, 4月 18, 2024

Growth, Financial Times, PPR

BERWYN, Pa., April 18, 2024 /PRNewswire/ -- PPR Capital Management (PPR), a private equity real estate investment firm, is pleased to announce that for the second year in a row, The Financial Times has recognized it as one of the Americas' Fastest Growing Companies.

Key Points:

BERWYN, Pa., April 18, 2024 /PRNewswire/ -- PPR Capital Management (PPR), a private equity real estate investment firm, is pleased to announce that for the second year in a row, The Financial Times has recognized it as one of the Americas' Fastest Growing Companies.
The annual high-profile list compiled by Statista and Financial Times is a visible and public acknowledgement of the 500 fastest-growing companies in the Americas that have the highest growth in publicly disclosed revenues between 2019 and 2022.
This period takes into account the pandemic and the end of rock-bottom interest rates.
"It is an honor for our firm to be recognized for the second year in a row by The Financial Times alongside many innovative, industry-leading companies," said Steve Meyer, CEO at PPR Capital Management.

Prairie Provident Resources Announces Fourth Quarter and Year-End 2023 Financial and Operating Results

Retrieved on:

火曜日, 4月 2, 2024

Evi, Natural gas, Sale, MD, Bank statement, TSX, PPR, CAD

CALGARY, Alberta, April 02, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its operating and financial results for the fourth quarter and year ended 2023.

Key Points:

CALGARY, Alberta, April 02, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its operating and financial results for the fourth quarter and year ended 2023.
Production averaged 3,413 boe/d (64% liquids) for the fourth quarter of 2023, a 9% decrease from the same period in 2022.
Fourth quarter 2023 operating netback1 before the impact of derivatives was $3.2 million ($10.03/boe), and $2.9 million ($9.07/boe) after realized losses on derivatives, a $3.4 million decrease and $0.6 million increase, respectively, from the fourth quarter of 2022.
Net capital expenditures1 for the fourth quarter of 2023 of $0.7 million were primarily for the retention of mineral and surface leases.

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Retrieved on:

火曜日, 3月 26, 2024

EEG, Central nervous system, Epilepsy, Patient, CNS, PPR, Pharmaceutical industry

BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. PPR studies measure electroencephalogram (EEG) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.

Key Points:

PPR studies measure electroencephalogram (EEG) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.
“The strength and consistency of response across both study arms, combined with a continued positive tolerability and safety profile, build on our earlier conviction that PRAX-628 has the potential to be the first precision sodium channel modulator for focal epilepsy patients.
With such a clear response, we have advanced our planning of the focal epilepsy efficacy study for PRAX-628, expected to begin in the second half of 2024.
We extend our thanks to the patients who participated in this PPR study,” said Marcio Souza, president and chief executive officer of Praxis.

Cable Blowing Equipment Market size is set to grow by USD 42.34 mn from 2024-2028, growing fiber optic deployment boost the market- Technavio

Retrieved on:

火曜日, 3月 19, 2024

View Sample Report

Key Points:

View Sample Report
Cable Blowing Equipment Market is fragmented ; the companies are competing with competitors and are trying to get greater market share.
Cable Blowing Equipment Market report includes information on the product launches, sustainability, and prospects of leading vendors including Adishwar Tele Networks Pvt.
This market encompasses various types of cable blowing machines, including PVC, PPR, and composite cable blowing equipment.
The market for cable blowing equipment is driven by the growing demand for reliable and efficient communication and power infrastructure.

AleutianStar JV Awarded Contract for Data Analytics Support with Department of State

Retrieved on:

火曜日, 3月 12, 2024

Propaganda, Democracy, Partnership, Nation, Strategic planning, Artificial intelligence, DOS, National security, Machine learning, PPR, Public diplomacy, Marketing, State, Public affairs

WASHINGTON, March 12, 2024 /PRNewswire/ -- AleutianStar JV, LLC (AleutianStar), has received a multi-year contract award by the Department of State's (DOS) Office of the Under Secretary for Public Diplomacy and Public Affairs (R), Office of Policy, Planning, and Resources (PPR) to provide comprehensive support for the DOS's public diplomacy efforts through advanced data analytics.

Key Points:

WASHINGTON, March 12, 2024 /PRNewswire/ -- AleutianStar JV, LLC (AleutianStar), has received a multi-year contract award by the Department of State's (DOS) Office of the Under Secretary for Public Diplomacy and Public Affairs (R), Office of Policy, Planning, and Resources (PPR) to provide comprehensive support for the DOS's public diplomacy efforts through advanced data analytics.
"This contract underscores our commitment to leveraging innovative technologies to drive positive outcomes for our clients.
By harnessing the power of data analytics, we aim to empower the DOS in its mission to engage effectively with global audiences."
This strategic partnership brings together two industry leaders with complementary expertise in data analytics and technology solutions.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on:

火曜日, 3月 5, 2024

Fourth Quarter and Full Year 2023 Financial Results:

Key Points:

Fourth Quarter and Full Year 2023 Financial Results:
As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

月曜日, 2月 26, 2024

HER2, PFS, AAAAI, KIT, Research, Completeness, TSS, ASCO, ASH, WT, Cash, Part, Safety, PEAK, AACR, Cogent, Conference, GIST, Society, PPR, Patient, The, PIPE, FGFR2, Clinical trial, Poster, G&A, Sunitinib, Initiate, IND, Brain, TKI, APEX, Cancer, American Academy, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.

Key Points:

and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.
SUMMIT is a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM).
Cash and Cash Equivalents: As of December 31, 2023, Cogent had cash, cash equivalents and marketable securities of $273.2 million.
During the quarter Cogent also completed and paid for bulk manufacturing campaigns of bezuclastinib to continue supporting the company’s clinical trials.

Prairie Provident Announces Year-End 2023 Reserves

Retrieved on:

木曜日, 2月 22, 2024

TP, PDP, RLI, Oil, Operational definition, National instrument, P+P, PPR

(1) PPR calculates Reserve Life Index (RLI) based on the estimated reserves amount as at December 31, 2023 for the relevant reserves category, as evaluated by Sproule, divided by actual 2023 annual production.

Key Points:

(1) PPR calculates Reserve Life Index (RLI) based on the estimated reserves amount as at December 31, 2023 for the relevant reserves category, as evaluated by Sproule, divided by actual 2023 annual production.
See “Cautionary Statements – Disclosure of Oil and Gas Reserves Data and Operational Information” and “Cautionary Statements – Reserve Life Index”.
This resulted in positive reserve additions of 0.3 MMboe, 0.1 MMboe, and 0.1 MMboe for PDP, TP, and P+P reserves, respectively.
The following table is a summary of the Company's estimated reserves as at December 31, 2023, as evaluated in the Sproule Report.